SAN DIEGO, Oct. 15, 2025 (GLOBE NEWSWIRE) -- Gyre Therapeutics (Nasdaq: GYRE), an innovative, commercial-stage biopharmaceutical company dedicated to advancing fibrosis-first therapies across organ systems affected by chronic disease, today announced that its indirect, majority-owned subsidiary, Gyre Pharmaceuticals Co., Ltd. (Gyre Pharmaceuticals), has completed patient enrollment in the 52-week Phase 3 clinical trial of its Class 1 drug, Pirfenidone capsules, for the treatment of pneumoconiosis. A total o ...

MONTREAL, Oct. 15, 2025 (GLOBE NEWSWIRE) -- Troilus Gold Corp. (TSX: TLG; OTCQX: CHXMF; FSE: CM5R) (“Troilus” or the “Company”) is pleased to report continued progress on the basic and detailed engineering of its copper-gold Troilus Project (the “Project”) led by engineering partner BBA Inc. (“BBA”) based in Montreal, Quebec. Basic engineering of the Project has now surpassed 85% completion, marking significant progress since the last engineering update provided on June 10, 2025. Following the completion of ...

Core Viewpoint - Taseko Mines Limited has made significant progress at its Florence Copper project, with the commencement of wellfield operations marking the start of commercial production, while also reporting strong operational results from its Gibraltar Mine in the third quarter of 2025 [1][2][4]. Florence Copper Project - Final regulatory approvals have been received, and wellfield operations are now starting, indicating the beginning of the commercial production facility [2]. - The SX/EW plant area has achieved substantial completion, with commissioning scheduled to run alongside wellfield operations, and first copper cathode production expected in approximately three months [3]. Gibraltar Mine Operations - In the third quarter, Gibraltar Mine produced 27.6 million pounds of copper, including 900 thousand pounds of copper cathode, and 560 thousand pounds of molybdenum, reflecting increases of 39% and 211% respectively compared to the previous quarter [4]. - Mill throughput reached the design capacity of 85,300 tons per day, with copper recoveries averaging 77% for the third quarter and 83% for September [4]. - Copper head grades were reported at 0.22%, showing improvement over the previous two quarters, although still behind plan [4]. Future Outlook - Mining at Gibraltar is advancing deeper into the Connector pit, with expectations of further production increases in the fourth quarter, although the production shortfall from recent months will not be fully recovered [5]. - Annual copper production for 2025 is projected to be between 100 to 105 million pounds [5]. - With rising copper prices and a focus on critical mineral supply security, the timing is favorable for Taseko to introduce a new source of refined copper in the U.S. [5].

Core Viewpoint - Alkane Resources Limited has updated its Mineral Resources and Ore Reserves estimates for its operations in Australia and Sweden, complying with the JORC Code, highlighting the strength and growth potential of the company [1][4]. Group Mineral Resources - Total Mineral Resources as of June 30, 2025, amount to 850,009 kt with a gold grade of 0.45 g/t, containing 12,143 koz of gold and 1.46 Mt of copper [2][8]. - Key locations include: - Tomingley: 20,254 kt at 2.25 g/t gold, containing 1,465 koz of gold [2][8]. - Boda Kaiser: 796,000 kt at 0.33 g/t gold and 0.18% copper, containing 8,280 koz of gold and 1.46 Mt of copper [2][8]. - Costerfield: 1,700 kt at 7.9 g/t gold and 2.3% antimony, containing 431 koz of gold and 39.4 kt of antimony [2][8]. - Björkdal: 32,055 kt at 1.91 g/t gold, containing 1,967 koz of gold [2][8]. Group Ore Reserves - Total Ore Reserves as of June 30, 2025, amount to 23,947 kt with an average gold grade of 1.7 g/t, containing 1,313 koz of gold and 10.7 kt of antimony [3][8]. - Key locations include: - Tomingley: 10,362 kt at 1.9 g/t gold, containing 620 koz of gold [3][8]. - Costerfield: 537 kt at 8.7 g/t gold and 2.0% antimony, containing 150 koz of gold and 10.7 kt of antimony [3][8]. - Björkdal: 13,048 kt at 1.3 g/t gold, containing 543 koz of gold [3][8]. Company Overview - Alkane operates three mines: Tomingley in New South Wales, Costerfield in Victoria, and Björkdal in Sweden, with ongoing exploration to enhance resource bases [4][5][6]. - The company is also developing the Boda-Kaiser Project, a significant gold-copper porphyry project, indicating a strong growth trajectory [7][4].

Core Points - Keros Therapeutics has entered into agreements to repurchase all shares held by ADAR1 Capital Management and Pontifax Venture Capital for approximately $181 million at a price of $17.75 per share, as part of a $375 million capital return program [1][4] - The company plans to commence a tender offer to repurchase up to $194 million of additional shares at the same price of $17.75 per share, expected to start by the end of October 2025 [3][4] - Keros intends to distribute 25% of any net cash proceeds from its global license agreement with Takeda Pharmaceuticals to stockholders by December 31, 2028 [2] Financial Details - The total purchase price for the repurchase of shares from ADAR1 and Pontifax is approximately $181 million, funded from existing cash and cash equivalents [1] - The planned tender offer will also be funded from the company's existing cash and cash equivalents [3] Management and Strategic Outlook - The capital return program reflects Keros' confidence in its outlook and the prospects for its key clinical program, KER-065, which is targeted for a Phase 2 clinical trial in patients with Duchenne muscular dystrophy in Q1 2026 [4] - The negotiation and approval of the repurchase transactions were overseen by a Capital Return Committee composed entirely of independent directors, ensuring a focus on enhancing long-term stockholder value [4]

Group 1 - Orange has acknowledged the decision of Group Altice to reject the joint non-binding offer made by Bouygues Telecom, Orange, and Free-Group Iliad [1] Group 2 - Orange is a leading telecommunications operator with revenues of €40.3 billion in 2024 and a workforce of 124,600 employees globally as of June 30, 2025, including 68,700 in France [2] - The company serves a total customer base of 300 million worldwide, comprising 262 million mobile customers and 22 million fixed broadband customers as of June 30, 2025 [2] - Orange operates in 26 countries and is a prominent provider of global IT and telecommunications services to multinational companies under the brand Orange Business [2] - The strategic plan "Lead the Future," introduced in February 2023, focuses on a new business model emphasizing responsibility and efficiency, leveraging network excellence to enhance service quality [2]

Core Points - CNH will announce its financial results for Q3 2025 on November 7, 2025, with a live webcast starting at 11:30 a.m. ET [1] - A replay of the financial results conference call will be available for 12 months on the corporate website [1] Company Overview - CNH Industrial (NYSE: CNH) is a global leader in equipment, technology, and services, focusing on innovation, sustainability, and productivity [3] - The company offers a wide range of agricultural and construction products through its brands, including Case IH, New Holland, and others [3] - CNH has a workforce of over 35,000 employees, emphasizing a diverse and inclusive workplace [4]

Core Insights - Ferrellgas Partners, L.P. reported growth in annual sales volume, revenue, gross profit, and adjusted EBITDA for fiscal year 2025, despite a decrease in adjusted EBITDA for the fourth quarter [2][5]. Financial Highlights - For the fourth fiscal quarter, adjusted EBITDA decreased by $10.5 million, or 31%, to $23.1 million compared to $33.6 million in the prior year quarter, primarily due to increased general and administrative expenses and operating expenses [3][4]. - For fiscal 2025, adjusted EBITDA increased by $13.3 million, or 4%, to $330.7 million compared to $317.4 million in fiscal 2024, driven by a $39.7 million increase in gross profit [5][6]. - Gross profit for fiscal 2025 reached over $1.0 billion, a 4% increase, attributed to a $101.2 million increase in revenues, partially offset by a $61.5 million increase in cost of product [6][10]. Operational Highlights - Gallons sold for the fourth fiscal quarter decreased by 3.3 million gallons, or 2%, but increased by 20.4 million gallons, or 3%, for fiscal 2025 [12]. - Retail sales increased by $2.9 million, or 2%, for the fourth fiscal quarter and $48.3 million, or 4%, for fiscal 2025, with growth across all customer types except agricultural customers [13]. - Wholesale sales increased by $0.4 million, or 0.2%, for the fourth fiscal quarter and $41.6 million, or 8%, for fiscal 2025 [14]. Expense Analysis - The increase in operating expenses for fiscal 2025 was $24.7 million, driven by increases in plant and other expenses and personnel costs [5][7]. - Interest expense increased by $9.8 million, primarily due to higher amortization of debt issuance costs and other interest charges [8]. Net Loss - The company recognized a net loss attributable to Ferrellgas Partners, L.P. of $26.8 million for the fourth fiscal quarter and $15.6 million for fiscal 2025, compared to net earnings of $110.2 million in fiscal 2024 [9][22].

Core Insights - Biodesix, Inc. is set to present preliminary data from the CLARIFY study at the 2025 CHEST Annual Meeting, focusing on lung nodule management and the performance of Nodify tests [1][2]. Group 1: CLARIFY Study Overview - The CLARIFY study aims to validate the performance of Nodify CDT and Nodify XL2 tests through a retrospective chart review of up to 4,000 patients, with a focus on diverse patient subgroups [2]. - The study began patient enrollment shortly after the 2024 CHEST Annual Meeting and has already enrolled 1,000 patients for interim analysis [2]. Group 2: Presentations at CHEST Annual Meeting - A national analysis on lung nodule management will be presented, emphasizing the need for structured approaches to optimize healthcare resource utilization and improve patient outcomes [3]. - Multiple independent presentations will highlight the clinical value of Nodify Lung tests in various real-world patient populations [3]. Group 3: Additional Presentations - Specific presentations include comparisons of the Nodify XL2 test with PET/CT for evaluating malignancy in pulmonary nodules and the impact of Nodify Lung Test strategy in risk stratification [4]. - Other topics include the association of lung cancer screening with proteomic testing in minority communities and retrospective analyses of Biodesix biomarkers [4]. Group 4: Company Vision and Market Context - Biodesix emphasizes the transformative potential of biomarkers in lung diagnostics, coinciding with Lung Cancer Awareness Month starting November 1 [5]. - The company is dedicated to improving clinical care and outcomes for patients with lung disease through its diagnostic tests and development services [5].

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement. MONGOLIAN MINING CORPORATION (Incorporated in the Cayman Islands with limited liability) (Stock Code: 975) OPERATIONAL UPDATE FOR THE QUARTER E ...